Skip to main content

Cell Line Development Market to Surpass Market Valuation of USD 15.88 Billion by 2031 | SkyQuest Technology

Written by Customer Service on . Posted in Mergers And Acquisitions.

Growing at a CAGR of 9.84% during the forecast period (2024-2031).

Westford, USA, Nov. 13, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Global Cell Line Development Market will reach a value of USD 15.88 Billion by 2031, with a CAGR of 12.12% during the forecast period (2024-2031). Cell line development, or CLD, will likely become popular as more and more biopharmaceutical companies start sprouting up. Cells are used as an expression host by most biopharma companies to synthesise recombinant monoclonal antibodies and proteins. The market is expected to grow in the upcoming years due to the availability of improved technologies for producing novel cell lines, as well as an increase in demand for cancer medicines and monoclonal antibodies.

Download a detailed overview:
https://www.skyquestt.com/sample-request/cell-line-development-market

Cell Line Development Market Overview:

Report Coverage Details 
Market Revenue in 2023 USD 6.36 Billion 
Estimated Value by 2031 USD 15.88 Billion 
Growth Rate Poised to grow at a CAGR of 12.12% 
Forecast Period 2024–2031 
Forecast Units Value (USD Billion) 
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends 
Segments Covered Product, Source, Type of Cell Line, Application and Region 
Geographies Covered North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa 
Report Highlights Development and commercialization of biogenerics and biosimilars
Key Market Opportunities Favorable government support
Key Market Drivers Growing prevalence of chronic diseases

Reagents and Media to Hold Significant Growth due to Critical Role in Maintaining Cell Health

In global cell line development market, reagents and media products lead due to their crucial role in maintaining cell health, enhancing growth conditions and increasing production of biopharmaceuticals. Rising demand for biologics as well as advances in cell culture techniques are fueling market growth with escalating needs for quality reagents.

Recombinant Cell Lines to Lead the Market due to Consistent Therapeutic Proteins for Biopharmaceutical Applications

The production of uniform, high-yield therapeutic proteins for biopharmaceutical uses has made recombinant cell lines the industry leader in cell line development globally. Efficient recombinant systems are deemed necessary to enable market expansion through improved stability, scalability, and cost-effectiveness in medication manufacture, which is made possible by the growing need for biosimilars and monoclonal antibodies.

North America to Dominate the Market Due to Strong Biopharmaceutical R&D

Rich in biopharmaceutical R&D, sophisticated healthcare infrastructure, and substantial biotechnology investment, North America dominates the global cell line development market. A well-established pharmaceutical industry, favourable regulatory frameworks, and the region’s expertise in drug research and development fuel demand for cutting-edge cell line creation technology.

Request Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/cell-line-development-market

Cell Line Development Market Insight

Drivers:

  1. Rising Demand for Biologics
  2. Growth in Biopharmaceutical R&D
  3. Expansion of Contract Research Organizations (CROs)

Restraints:

  1. Risk of Contamination
  2. Intellectual Property Issues
  3. Limited Cell Line Diversity

Prominent Players in Cell Line Development Market
The following are the Top Cell Line Development Companies:

  • Thermo Fisher Scientific (USA)
  • Lonza Group (Switzerland)
  • Merck KGaA (Germany)
  • Sartorius AG (Germany)
  • GE Healthcare (USA)
  • WuXi AppTec (China)
  • Danaher Corporation (USA)
  • Selexis SA (Switzerland)
  • Sigma-Aldrich (USA)
  • Corning Incorporated (USA)

View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/cell-line-development-market

 Key Questions Answered in Global Cell Line Development Market Report

  • What is the estimated market size for cell line development globally by 2031, and what is the anticipated compound annual growth rate (CAGR) for the 2024–2031 projection period?
  • Why do media and reagent goods command such a strong market share in the global cell line development industry?
  • Which geographical region leads the global cell line development market, and what elements support this dominance?

This report provides the following insights:

  • Analysis of key drivers (Increasing demand for biologic drugs, need for robust cell line development, innovations in cell culture techniques), restraints (Developing stable cell lines, regulatory approvals for cell line-based therapies, small number of standardized cell lines), opportunities (Producing viral vectors, growing interest in gene therapy, AI-driven tools for optimizing cell line development workflows), and challenges (Public concerns about the use of GMOs, maintaining CLD product consistency & quality) influencing the growth of cell line development market.
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the cell line development market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the cell line development market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the market
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Related Reports:

  1.  Digital Health Market is growing at a CAGR of 18.6% over the forecast period (2024–2031).  
  1.  Digital Therapeutics Market is growing at a CAGR of 16.61% during the forecast period (2024-2031).
  1.  Biosimilars Market is growing at a CAGR of 16.4% over the forecast period (2024-2031).  
  1.  Regenerative Medicine Market is growing at a CAGR of 27.2% in the forecast period (2024-2031).
  1.  3D Cell Culture Market is growing at a CAGR of 18.2% during the forecast period (2024-2031). 

 

About Us:

SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology. 

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Contact:

Mr. Jagraj Singh

SkyQuest Technology

1 Apache Way,

Westford,

Massachusetts 01886

USA (+1) 351-333-4748

Email: sales@skyquestt.com

Visit Our Website: https://www.skyquestt.com/

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.